BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 9721875)

  • 1. Inhibition of cancer cell growth and c-Myc transcriptional activity by a c-Myc helix 1-type peptide fused to an internalization sequence.
    Giorello L; Clerico L; Pescarolo MP; Vikhanskaya F; Salmona M; Colella G; Bruno S; Mancuso T; Bagnasco L; Russo P; Parodi S
    Cancer Res; 1998 Aug; 58(16):3654-9. PubMed ID: 9721875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retro-inverso peptide homologous to helix 1 of c-Myc is a potent and specific inhibitor of proliferation in different cellular systems.
    Pescarolo MP; Bagnasco L; Malacarne D; Melchiori A; Valente P; Millo E; Bruno S; Basso S; Parodi S
    FASEB J; 2001 Jan; 15(1):31-33. PubMed ID: 11099487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequence specific peptidomimetic molecules inhibitors of a protein-protein interaction at the helix 1 level of c-Myc.
    Nieddu E; Melchiori A; Pescarolo MP; Bagnasco L; Biasotti B; Licheri B; Malacarne D; Tortolina L; Castagnino N; Pasa S; Cimoli G; Avignolo C; Ponassi R; Balbi C; Patrone E; D'arrigo C; Barboro P; Vasile F; Orecchia P; Carnemolla B; Damonte G; Millo E; Palomba D; Fassina G; Mazzei M; Parodi S
    FASEB J; 2005 Apr; 19(6):632-4. PubMed ID: 15671156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and properties of a Myc derivative that efficiently homodimerizes.
    Soucek L; Helmer-Citterich M; Sacco A; Jucker R; Cesareni G; Nasi S
    Oncogene; 1998 Nov; 17(19):2463-72. PubMed ID: 9824157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mad1 expression in the absence of differentiation: effect of cAMP on the B-lymphoid cell line Reh.
    Naderi S; Blomhoff HK
    J Cell Physiol; 1999 Jan; 178(1):76-84. PubMed ID: 9886493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mmip1: a novel leucine zipper protein that reverses the suppressive effects of Mad family members on c-myc.
    Gupta K; Anand G; Yin X; Grove L; Prochownik EV
    Oncogene; 1998 Mar; 16(9):1149-59. PubMed ID: 9528857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: function and regulation.
    Lüscher B; Larsson LG
    Oncogene; 1999 May; 18(19):2955-66. PubMed ID: 10378692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of Mxi1 inhibits the induction of the human ornithine decarboxylase gene by the Myc/Max protein complex.
    Wu S; Peña A; Korcz A; Soprano DR; Soprano KJ
    Oncogene; 1996 Feb; 12(3):621-9. PubMed ID: 8637719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of the bHLH-zip domain of c-Myc with H1-type peptides. Characterization of helicity in the H1 peptides by NMR.
    Draeger LJ; Mullen GP
    J Biol Chem; 1994 Jan; 269(3):1785-93. PubMed ID: 8294427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of casein kinase II phosphorylation sites in Max: effects on DNA-binding kinetics of Max homo- and Myc/Max heterodimers.
    Bousset K; Henriksson M; Lüscher-Firzlaff JM; Litchfield DW; Lüscher B
    Oncogene; 1993 Dec; 8(12):3211-20. PubMed ID: 8247525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. c-Myc does not require max for transcriptional activity in PC-12 cells.
    Ribon V; Leff T; Saltiel AR
    Mol Cell Neurosci; 1994 Jun; 5(3):277-82. PubMed ID: 8087425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA binding by N- and L-Myc proteins.
    Ma A; Moroy T; Collum R; Weintraub H; Alt FW; Blackwell TK
    Oncogene; 1993 Apr; 8(4):1093-8. PubMed ID: 8455937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of transcription factors c-Myc, Max, and c-Myb by casein kinase II.
    Bousset K; Oelgeschläger MH; Henriksson M; Schreek S; Burkhardt H; Litchfield DW; Lüscher-Firzlaff JM; Lüscher B
    Cell Mol Biol Res; 1994; 40(5-6):501-11. PubMed ID: 7735324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. myc, max, and a novel rlf-L-myc fusion protein in small-cell lung cancer.
    Västrik I; Mäkelä TP; Koskinen PJ; Saksela K; Alitalo K
    Princess Takamatsu Symp; 1991; 22():307-18. PubMed ID: 1668890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low molecular weight inhibitors of Myc-Max interaction and function.
    Yin X; Giap C; Lazo JS; Prochownik EV
    Oncogene; 2003 Sep; 22(40):6151-9. PubMed ID: 13679853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Both the helix-loop-helix and the leucine zipper motifs of c-Myc contribute to its dimerization specificity with Max.
    Davis LJ; Halazonetis TD
    Oncogene; 1993 Jan; 8(1):125-32. PubMed ID: 8423990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oligopeptides impairing the Myc-Max heterodimerization inhibit lung cancer cell proliferation by reducing Myc transcriptional activity.
    D'Agnano I; Valentini A; Gatti G; Chersi A; Felsani A
    J Cell Physiol; 2007 Jan; 210(1):72-80. PubMed ID: 16998799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional interaction of the c-Myc transactivation domain with the TATA binding protein: evidence for an induced fit model of transactivation domain folding.
    McEwan IJ; Dahlman-Wright K; Ford J; Wright AP
    Biochemistry; 1996 Jul; 35(29):9584-93. PubMed ID: 8755740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of the widely expressed dMax splice variant of Max on E-box vs initiator element-mediated regulation by c-Myc.
    FitzGerald MJ; Arsura M; Bellas RE; Yang W; Wu M; Chin L; Mann KK; DePinho RA; Sonenshein GE
    Oncogene; 1999 Apr; 18(15):2489-98. PubMed ID: 10229200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Myc-interacting proteins: a second Myc network emerges.
    Sakamuro D; Prendergast GC
    Oncogene; 1999 May; 18(19):2942-54. PubMed ID: 10378691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.